MARKET

CNTA

CNTA

Centessa Pharmaceuticals Plc
NASDAQ
40.00
+12.42
+45.01%
Opening 11:29 03/31 EDT
OPEN
40.05
PREV CLOSE
27.58
HIGH
40.25
LOW
39.81
VOLUME
25.10M
TURNOVER
--
52 WEEK HIGH
40.25
52 WEEK LOW
9.60
MARKET CAP
5.84B
P/E (TTM)
-21.9211
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CNTA last week (0323-0327)?
Weekly Report · 1d ago
Centessa Pharmaceuticals Has Been Quietly Burning Through Cash. Next Week, Investors Find Out If the Pipeline Is Worth It.
Barchart · 1d ago
Weekly Report: what happened at CNTA last week (0316-0320)?
Weekly Report · 03/23 10:23
Payroll Figures Due in Canada Next Week
Barchart · 03/23 00:50
Centessa’s ORX750 Poised as Potential Best-in-Class Orexin Agonist with Upcoming Phase 2a Catalyst and Favorable Risk–Reward
TipRanks · 03/19 19:35
Centessa Extends ORX750 Narcolepsy Study: What Investors Should Watch Now
TipRanks · 03/19 16:33
Weekly Report: what happened at CNTA last week (0309-0313)?
Weekly Report · 03/16 10:22
Why Centessa Pharmaceuticals (CNTA) Is Up 5.7% After Advancing ORX750 Toward Registrational Sleep-Disorder Trials
Simply Wall St · 03/12 18:35
More
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Webull offers Centessa Pharmaceuticals PLC - ADR stock information, including NASDAQ: CNTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTA stock methods without spending real money on the virtual paper trading platform.